Skip to content

US · CGTX · BIOTECHNOLOGY

Cognition Therapeutics, Inc. (CGTX) intrinsic value and stock valuation

$0.58as of 2026-11-21 · Mkt cap 94.87M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Cognition Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values CGTX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from CGTX’s statements →

Cognition Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Purchase, NY 10577 cogrx.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$0.00
20192025
Net income
-$-23.49M
20192025
Free cash flow
-$-24.59M
20192025
Total equity
$34.3M
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-47.8M-$-53.97M-$-50.72M-$-43.55M-$-28.6M
Net income-$-23.49M-$-33.97M-$-25.79M$760K-$-11.72M
EPSd-$-322.8K-$-855.02K-$-858.81K$26.2K-$-527.22K
Operating cash flow-$-24.59M-$-28.47M-$-16.02M-$-18.53M-$-3.63M
Capital expenditure$0.00-$0.00-$-150K-$-170K-$-30K
Free cash flow-$-24.59M-$-28.48M-$-16.16M-$-18.7M-$-3.66M
Total assets$48.4M$30.2M$35.2M$50.4M$59.1M
Total debt$640K$810K$1.24M$1.48M$0.00
Net debt-$-36.17M-$-24.2M-$-28.68M-$-40.08M-$-54.72M
Total equity$34.3M$18.8M$24.5M$40.3M$51.3M
Cash and short-term investments$36.8M$25M$29.9M$41.6M$54.7M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$230K$0.00
Gross profit$0.00$0.00$0.00-$-230K$0.00
Research and development expenses$37.2M$41.7M$37.2M$30.3M$18.6M
Selling, general and administrative expenses$10.6M$12.3M$13.5M$13.2M$10M
Other expenses$0.00$0.00$0.00-$-230K$0.00
Operating expenses$47.8M$54M$50.7M$43.3M$28.6M
Cost and expenses$47.8M$54M$50.7M$43.6M$28.6M
Interest income$0.00$0.00$24.8M$22.2M$17.5M
Interest expense$10K$30K$30K$30K$890K
Depreciation and amortization$230K$270K$250K$230K$90K
Ebitda-$-23.25M-$-33.68M-$-25.51M-$-21.13M-$-10.73M
Operating income-$-47.8M-$-53.97M-$-50.72M-$-43.55M-$-28.6M
Total other income/expenses, net$24.3M$20M$24.9M$22.2M$16.9M
Income before tax-$-23.49M-$-33.97M-$-25.79M-$-21.4M-$-11.72M
Income tax expense$0.00$0.00$0.00-$-22.15M$0.00
Net income-$-23.49M-$-33.97M-$-25.79M$760K-$-11.72M
Weighted average shares outstanding$72.8M$39.7M$30M$29M$22.2M
Weighted average diluted shares outstanding$72.8M$39.7M$30M$29M$22.2M
Balance sheet
20252024202320222021
Cash and short-term investments$36.8M$25M$29.9M$41.6M$54.7M
Net receivables$9.92M$2.69M$1.28M$3.67M$2.27M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$48M$29.6M$34.2M$47.7M$59M
Property, plant and equipment, net$400K$680K$940K$1.05M$140K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$400K$680K$940K$2.78M$140K
Total assets$48.4M$30.2M$35.2M$50.4M$59.1M
Accounts payable$1.12M$1.98M$3.69M$3.22M$4.17M
Short-term debt$440K$470K$720K$780K$0.00
Deferred revenue$370K$1.07M$1.7M$1.7M$750K
Total current liabilities$13.9M$11.1M$10.2M$7.79M$7.86M
Long-term debt$200K$340K$520K$690K$0.00
Deferred revenue, non-current$0.00$0.00$0.00$1.69M$0.00
Total non-current liabilities$200K$340K$520K$2.38M$0.00
Capital lease obligations$330K$540K$690K$840K$0.00
Total liabilities$14.1M$11.5M$10.7M$10.2M$7.86M
Common stock$90K$60K$30K$30K$20K
Retained earnings-$-198.65M-$-175.16M-$-141.19M-$-115.4M-$-94M
Accumulated other comprehensive income (loss)$0.00$0.00-$-200K-$-200K-$-200K
Total equity$34.3M$18.8M$24.5M$40.3M$51.3M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$640K$810K$1.24M$1.48M$0.00
Net debt-$-36.17M-$-24.2M-$-28.68M-$-40.08M-$-54.72M
Cash flow statement
20252024202320222021
Net income-$-23.49M-$-33.97M-$-25.79M-$-21.4M-$-11.72M
Depreciation and amortization$230K$270K$250K$230K$90K
Stock-based compensation$2.09M$3.75M$4.35M$3.57M$5.18M
Change in working capital-$-3.46M$1.29M$4.85M-$-940K$2.84M
Accounts receivable-$-7.24M-$-1.41M$2.39M-$-1.41M-$-1.11M
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$3.51M$0.00$0.00-$-1.09M$2.17M
Net cash provided by operating activities-$-24.59M-$-28.47M-$-16.02M-$-18.53M-$-3.63M
Investments in property, plant and equipment$0.00-$0.00-$-150K-$-170K-$-30K
Acquisitions, net$10K$0.00$0.00$0.00$0.00
Net cash used for investing activities$10K-$0.00-$-150K-$-170K-$-30K
Common stock issued$37.1M$24.4M$5.33M$5.32M$44.2M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$36.6M$23.6M$4.52M$5.55M$53.2M
Net change in cash$12M-$-4.91M-$-11.64M-$-13.16M$49.5M
Cash at end of period$37M$25M$29.9M$41.6M$54.7M
Operating cash flow-$-24.59M-$-28.47M-$-16.02M-$-18.53M-$-3.63M
Capital expenditure$0.00-$0.00-$-150K-$-170K-$-30K
Free cash flow-$-24.59M-$-28.48M-$-16.16M-$-18.7M-$-3.66M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Cognition Therapeutics, Inc.

        Cognition Therapeutics, Inc. is a biopharmaceutical company in the clinical stage, focused on identifying and advancing small molecule treatments. The firm's research and development efforts are primarily directed towards age-related neurodegenerative conditions affecting the central nervous system, as well as retinal disorders. Its most advanced experimental therapy is CT1812, which acts as a sigma-2 receptor antagonist. This compound is currently being evaluated in Phase II clinical trials for the management of mild-to-moderate Alzheimer's disease and dementia with Lewy bodies (DLB). Additionally, it has successfully concluded Phase I trials for early-stage Alzheimer's and is undergoing preclinical investigation for dry age-related macular degeneration (AMD). The company's pipeline also includes CT2168, a treatment candidate for synucleinopathies—a category of diseases encompassing DLB and Parkinson's disease—and CT2074, which is in development for dry AMD. Cognition Therapeutics, Inc. was established in 2007 and operates from its headquarters in Purchase, New York.

        CEO
        Lisa Ricciardi
        Employees
        14
        Beta
        1.75

        Explore

        Frequently asked questions

        What is the intrinsic value of Cognition Therapeutics, Inc. (CGTX)?

        InvestorsCraft does not currently publish an intrinsic value for CGTX. How the IC value is calculated.

        Is CGTX undervalued?

        InvestorsCraft does not publish an undervaluation signal for CGTX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.